Why doctors can't simply prescribe most peptides, or get insurance to pay for them

By · Published · 6 min read · 8 sources, 8 checked at the source

Illustration of two empty armchairs facing each other across a small table with a notebook and clipboard, two speech bubbles with question marks and a plant.

Plenty of patients, and plenty of clinicians, have asked the same thing this year: if a doctor thinks a peptide like BPC-157 is worth trying, why can't they just write the prescription and send it to insurance? The short answer is that federal law sorts drugs by approval status, and most wellness peptides have never gone through FDA approval. HHS's new policy widened one door for six of them. Here is how each path works, where the new policy helps, and where the rules still stop doctors.

Facts are as of October 30, 2026. Sources, with retrieval dates, are at the bottom.

The gist

  • A doctor can prescribe an FDA-approved drug for a use it isn't approved for. FDA's consumer page says doctors generally may do this when they judge it medically appropriate. [V] That freedom only covers drugs FDA has already approved. [V]
  • For an unapproved peptide, the main route is a compounding pharmacy. HHS's policy, published in the Federal Register on October 30 at 91 FR 68526, says HHS won't bring enforcement cases over 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry compounding with six peptides, and it keeps the patient-specific prescription requirement. [V]
  • FDA's Expanded Access and the federal Right to Try law are built for serious or life-threatening illness, and Right to Try needs a drug with a completed Phase 1 trial and an active development program. [V]
  • The Medicaid drug definition in federal law starts from drugs FDA approved, and the same statute lets states leave out weight-loss agents. [V]
  • 6peptides covered by HHS's compounding enforcement policy [V]
  • 2 weekspublic comment window on that policy, counted from October 30 [V]
  • 1completed Phase 1 trial, the minimum before a drug can qualify under Right to Try [V]

Path 1: Off-label prescribing, which only works for approved drugs

The most flexible tool a doctor has is off-label prescribing. FDA's own explainer describes it as using an approved drug for a different condition, a different form or a different dose than the label lists. [V] After approval, FDA says, prescribers are generally free to use a drug for other purposes if they judge that medically appropriate. [V]

The catch is in the first word: approved. Several peptide medicines qualify, such as the GLP-1 drugs and tesamorelin, which we covered here. [V] BPC-157, TB-500, epitalon, KPV, MOTS-c and semax have no FDA-approved product, so there is nothing to prescribe off-label. [V]

Path 2: Compounding, where HHS just opened a door

Compounding is how a pharmacist, a doctor or an outsourcing facility combines or adjusts ingredients to make a drug for a particular patient. HHS uses that definition in its policy. [V] FDA's compounding Q&A says compounded drugs are not FDA-approved and can meet a real need when an approved drug isn't medically appropriate for a patient. [V]

Before this month, the main obstacle for peptides was FDA's interim category system for bulk ingredients. We explained it here. HHS's policy changes things for six peptides: if a licensed physician, a federal facility or a state-licensed pharmacy compounds using BPC-157, TB-500, epitalon, KPV, MOTS-c or semax, HHS says it won't bring an enforcement case. [V] The policy describes itself as a way to expand patient access. [V] Supporters of compounding access have pushed for exactly this kind of change, and you can read the full policy in our October 29 report.

The door has limits written into it. The policy covers 503A compounding only, and it keeps the patient-specific prescription rule and the ban on insanitary conditions. [V] It is an enforcement statement, not a rule, and the six peptides are not on the 503A bulks list in federal regulations. [V] Getting them on that list takes separate FDA rulemaking. [V] Comments on the policy are open for two weeks from October 30; our comment-period explainer covers what that window can and can't change.

Path 3: Expanded Access and Right to Try

Two federal pathways let patients reach drugs that are still in testing. Their entry rules are strict, and most wellness peptides don't fit them.

FDA's Expanded Access page, sometimes called "compassionate use," lists the conditions: a serious or immediately life-threatening disease, no comparable alternative, no way to join a trial, and a benefit that justifies the risk. [V]

Right to Try is narrower on the drug side. FDA's fact sheet says an eligible drug must have finished a Phase 1 trial, be in a trial meant to support approval or have an application filed, have an active investigational new drug application, and still be in active development. [V] The law doesn't require a company to provide the drug, and FDA doesn't review the requests. [V] For a peptide with no sponsor running a development program, there is usually no eligible product to request. [S]

“The Right to Try Act does not require a sponsor to provide an eligible investigational drug to an eligible patient.” [V]

FDA, Right to Try

Why insurance is a separate wall

Even when a doctor can prescribe and a pharmacy can compound, payment follows its own rules. In the Medicaid drug rebate statute, the definition of a "covered outpatient drug" begins with drugs approved under section 505 or 507 of the drug law, or older drugs sold before 1962 that meet certain conditions. [V] Medicare's Part D regulations build their drug definition on that same statutory section. [V] The same Medicaid statute also lets states exclude "agents when used for anorexia, weight loss, or weight gain." [V]

FDA's off-label page suggests patients ask whether their insurance will cover the treatment. [V] We did not review private insurers' or individual plans' compounding policies for this piece, so we can't say how any one plan handles a compounded peptide. [U] The federal definitions we read are built around approved products, which helps explain why compounded wellness peptides are usually paid for out of pocket. [S]

What could change this

  • FDA rulemaking on the 503A bulks list. Adding a peptide there would give compounding a firmer legal footing than an enforcement statement does. [V] No proposed rule had been published when we checked on October 30. [V]
  • The next FDA compounding advisory meeting. FDA plans to review five more peptide-related substances before the end of February 2027. We cover that meeting here. [V]
  • A sponsor running trials. An approved product is the only path to the label-based coverage and off-label freedom described above. [S]

Peptide Policy Watch

Why doctors can't simply prescribe most peptides, or get insurance to pay for them

Published October 30, 2026 · https://peptidepolicywatch.com/2026/10/30/why-doctors-cant-prescribe-or-get-peptides-covered/

Printable checklist

Questions for your clinician

General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.

  1. Is there an FDA-approved product for this use, or would it have to be compounded?
  2. If it's compounded, is the pharmacy state-licensed, and is the prescription written for one named patient?
  3. Does my plan cover compounded drugs at all, and how would I find out?
  4. Is there a registered clinical trial I could ask about?

Print view Select it, then use your browser’s Print command to print only this box.

Limits and unknowns

  • HHS's policy is new and may be revised after comments. We don't know how strictly state pharmacy boards will apply it. [U]
  • We read federal definitions, not each state's Medicaid list or any private plan, so coverage for a specific person may differ. [U]
  • The Social Security Administration's copy of section 1927 didn't load for us. We used the Cornell Legal Information Institute's copy of 42 U.S.C. 1396r-8 instead. [V]

Sources (retrieved October 30, 2026 unless noted)

  1. FDA, "Understanding Unapproved Use of Approved Drugs 'Off Label'," content current as of February 5, 2018 [V] — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
  2. FDA, "Compounding and the FDA: Questions and Answers," content current as of September 16, 2025 [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  3. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," with Appendices A and B [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  4. Federal Register, notice of availability for the HHS peptide policy, 91 FR 68526, FR Doc. 2026-22192, published October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  5. FDA, "Expanded Access," content current as of October 22, 2026 [V] — https://www.fda.gov/news-events/public-health-focus/expanded-access
  6. FDA, "Right to Try," content current as of December 12, 2024 [V] — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try
  7. 42 U.S.C. 1396r-8 (Social Security Act section 1927), via Cornell Legal Information Institute [V] — https://www.law.cornell.edu/uscode/text/42/1396r-8
  8. eCFR, 42 CFR 423.100, Part D definitions [V] — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-A/section-423.100

Spot a mistake? See how we source and our corrections policy.